HUTCHMED Presents R&D Update on Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251

HUTCHMED discusses its antibody-targeted therapy conjugates platform and lead candidate HMPL-A251 in a recent R&D update. The company's CMO and Head of R&D, Dr. Ming Shi, presented the first candidate at the EORTC meeting in Boston. The update highlighted the progress of the ATTC platform and the preliminary development plan for HMPL-A251. The late-stage pipeline progress was also discussed, with a closing remark and a Q&A session to follow.